Key result
Macrophage migration inhibitory factor (MIF) plays a key role in the pathogenesis of pulmonary arterial hypertension by promoting inflammation and hypoxia-induced vascular remodeling.
Why the study?
Does targeting macrophage migration inhibitory factor (MIF) with anti-MIFs have therapeutic potential in patients with pulmonary arterial hypertension?
Does targeting macrophage migration inhibitory factor (MIF) with anti-MIFs have therapeutic potential in patients with pulmonary arterial hypertension?
This review highlights the potential role of macrophage migration inhibitory factor (MIF) as a biomarker and therapeutic target in pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
MIF may serve as PAH biomarker or target; leaves open need for prospective clinical validation.
Ahmed et al. (2018) conducted a review in Pulmonary arterial hypertension. Macrophage migration inhibitory factor (MIF) inhibitors was evaluated. Macrophage migration inhibitory factor (MIF) plays a key role in the pathogenesis of pulmonary arterial hypertension by promoting inflammation and hypoxia-induced vascular remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: